Acquisition

18th August, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (‘SEBI Listing Regulations’) – acquisition of additional 40.67% stake in Yapan Bio Private Limited Dear Sir / Madam, This is further to our communication dated 10th August, 2026 regarding exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited (‘Yapan’), an associate company of the Company. We wish to inform you that the Company has completed the acquisition of 1,46,400 equity shares of ₹10 each of Yapan from its existing shareholders for an aggregate cash consideration of approximately ₹76 crores. Pursuant to the acquisition, the Company's shareholding in Yapan has increased from 33.33% to 74.00% of the equity share capital of Yapan. Consequent to the above acquisition, Yapan has ceased to be an associate company and has become a subsidiary of the Company. The promoter / promoter group of the Company is deemed to be indirectly interested in Yapan through the Company’s investment therein. Yapan, incorporated on 11th October, 2019, under the provisions of Companies Act, 2013, is a Contract Development and Manufacturing Organization, specializing in process development, characterization and Phase I/II GMP manufacturing services for vaccines and biologics. Revenue from operations of Yapan for FY2024, FY2025 and FY2026 was ₹26.91 crores, ₹54.40 crores and ₹26.34 crores, respectively. With this acquisition, PPL will fully embed Yapan’s advanced large molecule capabilities into its integrated service offering, enabling the Company to develop and scale complex biologic therapies with greater efficiency. Kindly take the above on record. Thank you, Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com